Drug
Simufilam
Simufilam: highest development phase Phase 3, developed by Cassava Sciences. 9 trial records tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Cassava Sciences
Trials
| Drug | Phase | Indication |
|---|---|---|
| Simufilam NCT04994483 | Phase 3 | Alzheimer Disease |
| Simufilam NCT05575076 | Phase 3 | Alzheimer Disease |
| Simufilam NCT05026177 | Phase 3 | Alzheimer Disease |
| Simufilam 100 mg tablet NCT04079803 | Phase 2 | Alzheimer Disease |
| simufilam NCT05352763 | Phase 2 | Alzheimer's Disease |
| Simufilam 100 mg oral tablet NCT04388254 | Phase 2 | Alzheimer Disease |
| simufilam NCT04932655 | Phase 1 | Healthy Volunteers |
| Simufilam NCT06390410 | Phase 1 | Hepatic Insufficiency |
| Simufilam NCT06195319 | Phase 1 | Absorption |
Latest
No recent events.
Follow Simufilam on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.